AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1860215 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg, alternate-day)
Number of subjects: 22071
Study 1860215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 6401257 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet based on Vivonex HN
Number of subjects: 70
Study 6401257 — intervention group
Group type: COMPARATOR
Intervention: Polymeric diet based on Clinifeed 400
Number of subjects: 70
Study 30153814 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived ability to handle stress and depressive mood without smoking
Number of subjects: 612
Study 30153814 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status in the week before baseline
Number of subjects: 612
Study 27632442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal high-voltage monophasic pulsed current (HVMPC) applied continuously for 50 minutes once a day, 5 times a week
Number of subjects: 49
Study 27632442 — intervention group
Group type: COMPARATOR
Intervention: Sham HVMPC
Number of subjects: 49
Study 24381040 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-Plan
Number of subjects: 68
Study 24381040 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 68
Study 23126676 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy under the Watt's protocol with adaptation to Chinese Culture (six weekly sessions of 90 minutes each)
Number of subjects: 60
Study 23126676 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated as before)
Number of subjects: 60
Study 20546160 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sevoflurane (IS)
Number of subjects: 59
Study 20546160 — intervention group
Group type: COMPARATOR
Intervention: Glucose and non-nutritive sucking (GNNS)
Number of subjects: 59
Study 18184957 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous every 6 hours for 5 days, then tapered over 6 days)
Number of subjects: 499
Study 18184957 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered every 6 hours for 5 days, then tapered over 6 days)
Number of subjects: 499
Study 18184957 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 499
Study 18184957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study 15897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen alone
Number of subjects: 233
Study 15897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen plus interferon alfa‐2b
Number of subjects: 233
Study 15897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b alone
Number of subjects: 233
Study 15897380 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 233
Study 15897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen
Number of subjects: 233
Study 15897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive peripheral blood mononuclear cell proliferation assay result
Number of subjects: 233
Study 15897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects (>40 years)
Number of subjects: 233
Study 12623811 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery for myopia correction (varied by group)
Number of subjects: 102
Study 10208073 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis
Number of subjects: 30
Study 10208073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral (CB) coping skills training
Number of subjects: 30
Study 10208073 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 8643424 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT (Miacalcic, Sandoz, nasal spray, 2 x 100 IU/day)
Number of subjects: 30
Study 8643424 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids (VR, Venoruton, Zyma, 2 x 0.6 + Vit. C. 0.2/day)
Number of subjects: 30
Study 8643424 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (AP, Apranax, 2 x 0.550/day)
Number of subjects: 30
Study 8643424 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT and VR
Number of subjects: 30
Study 8643424 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT as the first active drug
Number of subjects: 30
Study 2141691 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 22
Study 2141691 — intervention group
Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 22
Study 2141691 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 22
Study 343181 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2‐analogue SHB 286 (50‐200 microgram extravular dose)
Number of subjects: 94
Study 343181 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2‐analogue SHB 286 (1000‐2000 microgram intravenous infusion)
Number of subjects: 94
Study 343181 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2‐analogue SHB 286
Number of subjects: 94
Study 30414356 — intervention group
Group type: COMPARATOR
Intervention: Traditional 10-second signal averaged triplicates
Number of subjects: 0
Study 30414356 — intervention group
Group type: EXPERIMENTAL
Intervention: Three metrics using increasing density of automatically measured beat-to-beat (btb) intervals
Number of subjects: 0
Study 28885566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplement (3 g/day)
Number of subjects: 44
Study 28885566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 26338213 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogonality metrics (OMs) derived from convex hull, information theory, fractal dimension, correlation coefficients, nearest neighbor distances and bin-density techniques
Number of subjects: 47
Study 26338213 — intervention group
Group type: EXPERIMENTAL
Intervention: Clark and Evans method (nearest neighbor method)
Number of subjects: 47
Study 26338213 — intervention group
Group type: EXPERIMENTAL
Intervention: Products of OMs
Number of subjects: 47
Study 26338213 — intervention group
Group type: EXPERIMENTAL
Intervention: Global metric (convex hull relative area) and local metric (box-counting fractal dimension)
Number of subjects: 47
Study 23374027 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 20 μg/h (Butrans®)
Number of subjects: 0
Study 23374027 — intervention group
Group type: COMPARATOR
Intervention: BTDS 5 μg/h (Butrans®)
Number of subjects: 0
Study 21195151 — intervention group
Group type: EXPERIMENTAL
Intervention: GQD-RU486
Number of subjects: 90
Study 21195151 — intervention group
Group type: COMPARATOR
Intervention: RU486
Number of subjects: 90
Study 21195151 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 90
Study 19329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8 every 21 days (arm A)
Number of subjects: 165
Study 19329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 50 mg/m² days 1 and 15 plus gemcitabine 1600 mg/m² days 1 and 15 every 28 days (arm B)
Number of subjects: 165
Study 19329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² days 1 and 8 plus cisplatin 100 mg/m² day 2 every 21 days for 3 cycles followed by docetaxel 75 mg/m² day 1 every 21 days for 3 cycles (arm C)
Number of subjects: 165
Study 17942364 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus intervention (SC+I)
Number of subjects: 79
Study 15114770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with heart failure and arterial hypertension
Number of subjects: 192
Study 15114770 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 192
Study 11590384 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroid (440 microg fluticasone propionate [FP] twice per day)
Number of subjects: 12
Study 11590384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10211016 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 0
Study 10211016 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study 10211016 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine vs Bupivacaine
Number of subjects: 0
Study 8724019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose approximately equal to 15 mmol/l)
Number of subjects: 10
Study 8724019 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia
Number of subjects: 10
Study 2331068 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge spinal needle
Number of subjects: 28
Study 2331068 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge spinal needle
Number of subjects: 28
Study 452945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP)
Number of subjects: 7
Study 452945 — intervention group
Group type: COMPARATOR
Intervention: No intra-aortic balloon pumping (IABP)
Number of subjects: 7
Study 30375104 — intervention group
Group type: EXPERIMENTAL
Intervention: Paddles
Number of subjects: 125
Study 30375104 — intervention group
Group type: COMPARATOR
Intervention: Patches
Number of subjects: 125
Study 30375104 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Pressure Augmentation (MPA)
Number of subjects: 125
Study 28329359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training intervention (52-week or 26-week)
Number of subjects: 122
Study 28329359 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain analyses
Number of subjects: 122
Study 28329359 — intervention group
Group type: EXPERIMENTAL
Intervention: Other brain regions analysis
Number of subjects: 122
Study 25425136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 100
Study 25425136 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study 22520307 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional ultrasound (US)
Number of subjects: 2
Study 22520307 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound (US)
Number of subjects: 2
Study 19443246 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland disability questionnaire (RDQ) administered at T1 and T2
Number of subjects: 212
Study 19443246 — intervention group
Group type: EXPERIMENTAL
Intervention: Global perceived effect (GPE) scale at T2
Number of subjects: 212
Study 19443246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RDQ scores
Number of subjects: 212
Study 19443246 — intervention group
Group type: COMPARATOR
Intervention: Intervention (not specified)
Number of subjects: 212
Study 18188743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine craving, withdrawal symptoms, and smoking urges measured daily for 30 days post-quit date.
Number of subjects: 137
Study 18188743 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit day symptom scores for women who relapsed.
Number of subjects: 137
Study 15933856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise therapy
Number of subjects: 40
Study 15933856 — intervention group
Group type: COMPARATOR
Intervention: Range of motion (ROM) exercise
Number of subjects: 40
Study 15933856 — intervention group
Group type: COMPARATOR
Intervention: Control group (same dynamic exercise protocol)
Number of subjects: 40
Study 12790850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 121
Study 12790850 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension (LC)
Number of subjects: 121
Study 11034583 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-207266 (0.5, 5, and 20 mg doses)
Number of subjects: 70
Study 11034583 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-207266 (0.05, 0.5, or 5 mg)
Number of subjects: 70
Study 11034583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8543503 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (10 to 20 mg/kg every 8 h)
Number of subjects: 170
Study 8543503 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole
Number of subjects: 170
Study 8543503 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 170
Study 8543503 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime regimens
Number of subjects: 170
Study 2116610 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a (leuprolide acetate depot 3.75 mg every 28 days)
Number of subjects: 17
Study 2116610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7030228 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly cycled oscillating waterbed
Number of subjects: 14
Study 7030228 — intervention group
Group type: COMPARATOR
Intervention: Non-oscillating waterbed
Number of subjects: 14
Study 30975147 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefan®
Number of subjects: 200
Study 30975147 — intervention group
Group type: COMPARATOR
Intervention: Coartem®
Number of subjects: 200
Study 28566400 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty and supervised exercise treatment
Number of subjects: 140
Study 28566400 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise treatment alone
Number of subjects: 140
Study 26400874 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive medications
Number of subjects: 17000
Study 26400874 — intervention group
Group type: COMPARATOR
Intervention: Nighttime dosing of antihypertensive medications
Number of subjects: 17000
Study 23755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5 mg
Number of subjects: 48
Study 23755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg
Number of subjects: 48
Study 23755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg
Number of subjects: 48
Study 23755867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21364485 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Torque (CT) stretching
Number of subjects: 17
Study 21364485 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Angle (CA) stretching
Number of subjects: 17
Study 19138567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months
Number of subjects: 165
Study 19138567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 19138567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (thioridazine, chlorpromazine, haloperazine, trifluoperazine, or risperidone) for 12 months
Number of subjects: 165
Study 19138567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidone, trifluoperazine, or risperidone) for 12 months
Number of subjects: 165
Study 18236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions
Number of subjects: 63
Study 18236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioral interventions
Number of subjects: 63
Study 18236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored psychosocial and biological interventions
Number of subjects: 63
Study 14756608 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered, coping improvement group intervention
Number of subjects: 329
Study 11224633 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledochocholedochostomy with T tube
Number of subjects: 180
Study 11224633 — intervention group
Group type: COMPARATOR
Intervention: Choledochocholedochostomy without T tube
Number of subjects: 180
Study 10096047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh urine samples examined within 4 hours
Number of subjects: 40
Study 7819171 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 19
Study 7819171 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 19
Study 7819171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Latanoprost and Timolol
Number of subjects: 19
Study 7819171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Timolol and Latanoprost
Number of subjects: 19
Study 3337191 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha 1-isopropylester, 1.120 micrograms
Number of subjects: 20
Study 3337191 — intervention group
Group type: COMPARATOR
Intervention: Polysorbate 80 in saline (control)
Number of subjects: 20
Study 31841417 — intervention group
Group type: EXPERIMENTAL
Intervention: Error Augmentation (EA) in immersive VR
Number of subjects: 17
Study 31841417 — intervention group
Group type: COMPARATOR
Intervention: Training without Error Augmentation (EA)
Number of subjects: 17
Study 29770146 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 20 Hz rTMS applied to the left primary motor cortex for 5 consecutive days
Number of subjects: 6
Study 29770146 — intervention group
Group type: COMPARATOR
Intervention: Sham 20 Hz rTMS
Number of subjects: 6
Study 27387193 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Diagnostic Scale (PDS) and Center for Epidemiologic Studies‐Depression Scale (CES‐D)
Number of subjects: 104
Study 27387193 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Symptom Inventory (BSI) and CES‐D
Number of subjects: 104
Study 25398701 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-arrhythmic medication
Number of subjects: 2407
Study 25398701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-blocker
Number of subjects: 2407
Study 25398701 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 2407
Study 25398701 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Number of subjects: 2407
Study 25398701 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 2407
Study 25398701 — intervention group
Group type: EXPERIMENTAL
Intervention: Other cardiovascular and psychotropic medication
Number of subjects: 2407
Study 23769289 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Psychotherapy (BPT)
Number of subjects: 31
Study 23769289 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 31
Study 21432752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 40
Study 21432752 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 40
Study 18694635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 300 mg/day WS 5570
Number of subjects: 426
Study 18694635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 16823303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Number of subjects: 82
Study 16823303 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 82
Study 12707127 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 2 mg/kg
Number of subjects: 0
Study 10624972 — intervention group
Group type: EXPERIMENTAL
Intervention: F(IO)2 of 0.4 during one-lung ventilation (OLV)
Number of subjects: 24
Study 10624972 — intervention group
Group type: EXPERIMENTAL
Intervention: F(IO)2 of 0.6 during OLV
Number of subjects: 24
Study 10624972 — intervention group
Group type: EXPERIMENTAL
Intervention: F(IO)2 of 1.0 during OLV
Number of subjects: 24
Study 10624972 — intervention group
Group type: COMPARATOR
Intervention: Two-lung ventilation (TLV)
Number of subjects: 24
Study 15321262 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 7.5 microg (1.5 ml)
Number of subjects: 25
Study 15321262 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 5 microg + bupivacaine 1 mg (1.5 ml)
Number of subjects: 25
Study 15321262 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 1.75 mg, sufentanil 1.05 microg and epinephrine 1.75 microg (1.5 ml)
Number of subjects: 25
Study 1585754 — intervention group
Group type: EXPERIMENTAL
Intervention: UVAB (combined UVA-UVB)
Number of subjects: 0
Study 1585754 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA
Number of subjects: 0
Study 1585754 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB
Number of subjects: 0
Study 1585754 — intervention group
Group type: EXPERIMENTAL
Intervention: UVAB
Number of subjects: 0
Study 3897614 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:8 form
Number of subjects: 364
Study 3897614 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:6 form
Number of subjects: 364
Study 3897614 — intervention group
Group type: EXPERIMENTAL
Intervention: 6:4 form
Number of subjects: 364
Study 3897614 — intervention group
Group type: COMPARATOR
Intervention: CCL form
Number of subjects: 364
Study 30636281 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (Neurontin)
Number of subjects: 0
Study 30636281 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (Gabasandoz)
Number of subjects: 0
Study 30636281 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional batch of Gabapentin
Number of subjects: 0
Study 29049611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic up‐front surgery within 6 months from diagnosis combined with oncologic treatment
Number of subjects: 363
Study 29049611 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment or delayed surgery as needed combined with oncologic treatment
Number of subjects: 363
Study 26077904 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week behavioral intervention using video instructional materials, workbook and telephone coaching in behavioral management, pleasant events scheduling, and relaxation
Number of subjects: 0
Study 26077904 — intervention group
Group type: COMPARATOR
Intervention: Basic education guide and telephone support
Number of subjects: 0
Study 26077904 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week behavioral intervention
Number of subjects: 0
Study 24359036 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC intervention (four-session, multi-component intervention focused on reminiscence and future planning)
Number of subjects: 19
Study 24359036 — intervention group
Group type: COMPARATOR
Intervention: Minimal support phone contact (comparison group)
Number of subjects: 19
Study 22253270 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.01-0.3 mg/kg)
Number of subjects: 54
Study 22253270 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 54